POPULATION PHARMACOKINETICS OF GS-5718, AN ORAL INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) INHIBITOR, IN HEALTHY SUBJECTS.

被引：0
|
作者：
Sathe, A. [1 ]
Anderson, K. [1 ]
McFarlane, J. [1 ]
Othman, A. [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-152
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [1] Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
    Roedder, Silke
    Wendt, Emily
    Burris, Chad
    Nazareon, Jonathan
    Park, Grace
    Pangilinan, Phil
    Huang, Gianna
    Mathur, Anubhav
    Taylor, James
    Billin, Andrew
    Matzkies, Franziska
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 371 - 372
  • [2] Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4)
    Wang, Li
    Ferrao, Ryan
    Li, Qiubai
    Hatcher, John M.
    Choi, Hwan Geun
    Buhrlage, Sara J.
    Gray, Nathanael S.
    Wu, Hao
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (12) : 4511 - 4519
  • [3] Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults
    Agarwal, Sagar
    Mcdonald, Alice A.
    Campbell, Veronica
    Chen, Dapeng
    Davis, Jeff
    Rong, Haojing
    Mishkin, Aimee
    Slavin, Anthony
    Gollerkeri, Ashwin
    Gollob, Jared A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (03):
  • [4] Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects
    Lin, Yaoxiang
    Zheng, Lulu
    Xu, Ying
    Wang, Xinyan
    Li, Jie
    Zheng, Lei
    Liang, Guang
    Chen, Lingfeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 902 - 914
  • [5] Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)
    Seganish, W. Michael
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (08) : 917 - 932
  • [6] Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
    Spencer I. Danto
    Negin Shojaee
    Ravi Shankar P. Singh
    Cheryl Li
    Steven A. Gilbert
    Zorayr Manukyan
    Iain Kilty
    Arthritis Research & Therapy, 21
  • [7] Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
    Danto, Spencer, I
    Shojaee, Negin
    Singh, Ravi Shankar P.
    Li, Cheryl
    Gilbert, Steven A.
    Manukyan, Zorayr
    Kilty, Iain
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
  • [8] Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
    McElroy, William T.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2019, 29 (04) : 243 - 259
  • [9] Chilblains accompanying interleukin-1 receptor-associated kinase (IRAK)-4 deficiency
    Gurung, P.
    Lee, A. S. W.
    Armon, K.
    Millington, G. W. M.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (05) : 596 - 597
  • [10] Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer
    Feng, Yifan
    Chen, Chengjuan
    Shao, Anqi
    Wu, Lei
    Hu, Haiyu
    Zhang, Tiantai
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (12) : 5091 - 5105
12345